fax: (52) 81 8333-7747
1527-3350/asset/olbannerleft.gif?v=1&s=4b2409f9534ed500d3c8da1940a23842e2b9932d)
1527-3350/asset/olbannerright.gif?v=1&s=141b9a8485298533c3e2016e937b0404f7d933e1)
Viral Hepatitis
You have full text access to this OnlineOpen article
Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways†
Article first published online: 14 JAN 2008
DOI: 10.1002/hep.22215
Copyright © 2008 American Association for the Study of Liver Diseases
Additional Information
How to Cite
Trujillo-Murillo, K., Rincón-Sánchez, A. R., Martínez-Rodríguez, H., Bosques-Padilla, F., Ramos-Jiménez, J., Barrera-Saldaña, H. A., Rojkind, M. and Rivas-Estilla, A. M. (2008), Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways. Hepatology, 47: 1462–1472. doi: 10.1002/hep.22215
- †
Potential conflict of interest: Nothing to report.
- ‡
fax: (52) 81 8333-7747
Publication History
- Issue published online: 24 APR 2008
- Article first published online: 14 JAN 2008
- Accepted manuscript online: 14 JAN 2008 12:00AM EST
- Manuscript Accepted: 2 JAN 2008
- Manuscript Received: 16 AUG 2007
References
- 1
- 2, . Hepatitis C virus infection. N Engl J Med 2001; 345: 41–52.
- 3, , , . Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004; 39: 1147–1171.
- 4, . Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967–972.
- 5. Selective inhibitors of hepatitis C virus replication. Antiviral Res 2006; 71: 363–371.
- 6, , , , , . Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110–113.
- 7, . Novel cell culture systems for the HCV. Antiviral Res 2001; 52: 1–17.
- 8, , , , , , et al. Salicylates inhibit flavivirus replication independently of blocking NF-kappaB activation. J Virol 2001; 75: 7828–7839.
- 9, , , , , , et al. Acetylsalicylic acid blocks influenza virus propagation via its NF-kappaB-inhibiting activity. Cell Microbiol 2007; 9: 1683–1694.
- 10, , , , , , et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci U S A 1994; 91: 11202–11206.
- 11, , , , . COX-3: a splice variant of cyclooxygenase-1 in mouse neural tissue and cells. Brain Res Mol Brain Res 2003; 119: 213–215.
- 12, . Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: role of PGE2 in RNA replication. J Virol 2005; 79: 9725–9734.
- 13, , , , . An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes. J Biol Chem 2000; 275: 23627–23635.
- 14, , , , , . PKR-dependent mechanisms of gene expression from a subgenomic hepatitis C virus clone. J Virol 2002; 76: 10637–10653.
- 15, , , . Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7-RNA polymerase. Proc Natl Acad Sci U S A 1986; 83: 8122–8126.
- 16, . Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156–159.
- 17, , , , , , et al. Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of HCV. J Biol Chem 2005; 280: 9049–9057.
- 18, , , , , , et al. Oral prostaglandin (PGE2) therapy for chronic viral hepatitis B and C. J Viral Hepat 1999; 6: 329–336.Direct Link:
- 19, , , , , , et al. COX-2 induction during murine gammaherpesvirus 68 infection leads to enhancement of viral gene expression. J Virol 2003; 77: 12753–12763.
- 20, , , , . Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication. Proc Natl Acad Sci U S A 2002; 99: 3932–3937.
- 21, , , , , , et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001; 276: 18563–18569.
- 22, , , . Activation of p38 MAPK by sodium salicylate leads to inhibition of TNF-induced IkappaB-alpha phosphorylation and degradation. Mol Cell Biol 1998; 18: 78–84.
- 23, , , , . Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by cyclooxygenase-2 in coronary artery smooth muscle cells. Circ Res 1998; 83: 210–216.
- 24, , , . In vitro activity of ASA on replication of varicella-zoster virus. New Microbiol 1998; 21: 397–401.
- 25, , , , , , et al. Additive effect of ethanol and HCV subgenomic replicon expression on COX-2 protein levels and activity. J Viral Hepat 2007; 14: 608–617.
- 26, , , , . Effect of HCV core protein on cellular gene expression: specific inhibition of COX-2. J Infect Dis 2005; 191: 1498–1506.
- 27, , , , , . HCV core protein suppresses NF-kappaB activation and COX-2 expression by direct interaction with IkappaB kinase beta. J Virol 2005; 79: 7648–7657.
- 28, , , . Nonsteroidal antiinflammatory drugs lower ethanol-mediated liver increase in lipids and thiobarbituric acid reactive substances. Alcohol Clin Exp Res 1993; 17: 1228–1232.Direct Link:
- 29, , , , . Inhibition of cyclooxygenase activity reduces rotavirus infection at a postbinding step. J Virol 2004; 78: 9721–9730.
- 30, , , . Suppression of Japanese encephalitis virus infection by non-steroidal anti-inflammatory drugs. J Gen Virol 2002; 83: 1897–1905.
- 31. Oxidative stress during viral infection: a review. Free Radic Biol Med 1996; 21: 641–649.
- 32, , , , , , et al. Potential dengue virus-triggered apoptotic pathway in human neuroblastoma cells: arachidonic acid, superoxide anion, and NF-kappaB are sequentially involved. J Virol 2000; 74: 8680–8691.
- 33, , , , . Inhibitor SP600125 reduces COX-2 expression by attenuating mRNA in activated murine J774 macrophages. Int Immunopharmacol 2006; 6: 987–996.
- 34, , , , , , et al. Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha-interferon. HEPATOLOGY 1998; 27: 862–867.
- 35, , , , , , et al. Interferon-alpha combined with ketoprofen as treatment of naive patients with chronic hepatitis C: a randomized controlled trial. J Viral Hepat 2003; 10: 306–309.
- 36, , . Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic HCV infection. Liver Transpl 2003; 9: 57–61.
- 37, , , , , , et al. Interferon alfa-2b alone or in combination with ketoprofen as treatment for interferon-naive chronic hepatitis C patients. Aliment Pharmacol Ther 1999; 13: 1329–1334.
- 38, , , . Failure of ketoprofen and interferon combination therapy to improve interferon-resistant chronic hepatitis C. Can J Gastroenterol 1997; 11: 294–297.
- 39, , , , , . Nonsteroidal anti-inflammatory drug metabolism potentiates IFN-alfa signaling by increasing STAT1 phosphorylation. HEPATOLOGY 1999; 30: 510–516.
- 40, , , , , , et al. Interferon-alpha 2b combined with daily ketoprofen administration improves virological response in chronic hepatitis C: a prospective and randomised trial. Gut 2000; 46: 427–431.